Reported Tuberculosis in the United States, 2013
(PDF - 174k)
Table 10. Percentages of Tuberculosis Cases by Initial Drug Regimen, Use of Directly Observed Therapy (DOT), and Completion of Therapy (COT): United States, 1993–2011
Year | Initial Drug Regimen1,2 | Directly Observed Therapy3 | Therapy ≤1 Year Indicated4 | ||||
---|---|---|---|---|---|---|---|
I R | IRZ | IRZE | DOT Only | Both DOT and Self-Administered | COT ≤1 Year | COT | |
1993 | (13.0) | (31.2) | (40.3) | (21.7) | (14.4) | (63.4) | (86.0) |
1994 | (7.0) | (23.3) | (55.7) | (28.1) | (20.5) | (68.6) | (86.8) |
1995 | (5.2) | (20.3) | (62.7) | (37.3) | (21.5) | (74.1) | (89.2) |
1996 | (4.2) | (17.5) | (67.3) | (42.5) | (22.4) | (76.8) | (90.2) |
1997 | (3.2) | (15.1) | (71.9) | (47.0) | (23.8) | (78.7) | (91.0) |
1998 | (2.6) | (12.9) | (74.3) | (47.7) | (26.6) | (80.6) | (92.5) |
1999 | (2.2) | (11.2) | (76.9) | (49.4) | (27.6) | (81.4) | (92.2) |
2000 | (2.0) | (10.4) | (78.5) | (52.5) | (25.8) | (82.2) | (92.5) |
2001 | (1.7) | (9.6) | (79.8) | (53.6) | (27.5) | (82.5) | (92.7) |
2002 | (1.8) | (8.9) | (80.3) | (55.4) | (27.8) | (83.0) | (92.5) |
2003 | (1.4) | (8.1) | (81.3) | (56.5) | (28.5) | (83.6) | (92.8) |
2004 | (1.5) | (6.4) | (82.4) | (58.9) | (27.7) | (84.3) | (92.6) |
2005 | (1.3) | (5.5) | (83.7) | (57.9) | (29.6) | (84.0) | (92.5) |
2006 | (1.2) | (4.8) | (83.3) | (57.5) | (30.4) | (84.8) | (93.2) |
2007 | (1.1) | (4.6) | (83.6) | (56.3) | (32.9) | (85.6) | (93.9) |
2008 | (1.0) | (3.5) | (84.3) | (56.3) | (33.5) | (86.0) | (93.34) |
2009 | (0.9) | (3.1) | (84.6) | (59.5) | (30.3) | (88.7) | (95.5) |
2010 | (0.8) | (2.8) | (84.8) | (59.0) | (31.2) | (89.6) | (96.0) |
20115 | (0.7) | (2.6) | (85.2) | (62.0) | (29.3) | (89.0) | (95.7) |
1 Includes persons alive at diagnosis.
2 I=isoniazid; R=rifampin; Z=pyrazinamide; E=ethambutol. Excludes cases with no information on initial drug regimen; In 2013, 0.57% received no initial drug therapy, 0.02% were started on one drug, and 12.36% had an initial multidrug regimen other than IR, IRZ, or IRZE.
3 Includes persons alive at diagnosis with initial drug regimen of one or more drugs prescribed.
4 Includes persons alive at diagnosis, with initial drug regimen of one or more drugs prescribed, who did not die during therapy. Excludes persons with initial isolate rifampin resistant, or patient with meningeal disease, or pediatric patient (aged <15) with miliary disease or positive blood culture.
5 Beginning in 2011, those who moved out of country during treatment are excluded from the denominator of those eligible for COT.
Note: Data for all years updated through June 11, 2014.
See Technical Notes for description of COT calculation.
See Surveillance Slides #30 and #31.
- Page last reviewed: September 30, 2014
- Page last updated: September 30, 2014
- Content source: